Literature DB >> 21124322

ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease.

Luiza A Rabelo1, Natalia Alenina, Michael Bader.   

Abstract

The renin-angiotensin-aldosterone system (RAAS) is a pivotal regulator of physiological homeostasis and diseases of the cardiovascular system. Recently, new factors have been discovered, such as angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) and Mas. This newly defined ACE2-angiotensin-(1-7)-Mas axis was shown to have a critical role in the vasculature and in the heart, exerting mainly protective effects. One important mechanism of the classic and the new RAAS regulate vascular function is through the regulation of redox signaling. Angiotensin II is a classic prooxidant peptide that increases superoxide production through the activation of NAD(P)H oxidases. This review summarizes the current knowledge about the ACE2-angiotensin-(1-7)-Mas axis and redox signaling in the context of cardiovascular regulation and disease. By interacting with its receptor Mas, angiotensin-(1-7) induces the release of nitric oxide from endothelial cells and thereby counteracts the effects of angiotensin II. ACE2 converts angiotensin II to angiotensin-(1-7) and, thus, is a pivotal regulator of the local effects of the RAAS on the vessel wall. Taken together, the ACE2-angiotensin-(1-7)-Mas axis emerges as a novel therapeutic target in the context of cardiovascular and metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21124322     DOI: 10.1038/hr.2010.235

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  51 in total

1.  Angiotensin-(1-7) reverses angiogenic dysfunction in corpus cavernosum by acting on the microvasculature and bone marrow-derived cells in diabetes.

Authors:  Neha Singh; Goutham Vasam; Rahul Pawar; Yagna P R Jarajapu
Journal:  J Sex Med       Date:  2014-06-23       Impact factor: 3.802

Review 2.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

3.  Soluble thrombomodulin reduces inflammation and prevents microalbuminuria induced by chronic endothelial activation in transgenic mice.

Authors:  Gangaraju Rajashekhar; Akanksha Gupta; Abby Marin; Jessica Friedrich; Antje Willuweit; David T Berg; Martin S Cramer; George E Sandusky; Timothy A Sutton; David P Basile; Brian W Grinnell; Matthias Clauss
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-30

4.  Angiotensin-(1-7) administration benefits cardiac, renal and progenitor cell function in db/db mice.

Authors:  A M Papinska; N M Mordwinkin; C J Meeks; S S Jadhav; K E Rodgers
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

5.  Prolonged treatment with angiotensin 1-7 improves endothelial function in diet-induced obesity.

Authors:  Andreas M Beyer; Deng-Fu Guo; Kamal Rahmouni
Journal:  J Hypertens       Date:  2013-04       Impact factor: 4.844

6.  The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction.

Authors:  Saghir Akhtar; Ibrahim Fadil Benter
Journal:  Bioimpacts       Date:  2013-01-26

Review 7.  Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension.

Authors:  Rodrigo Araujo Fraga-Silva; Anderson Jose Ferreira; Robson Augusto Souza Dos Santos
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

8.  Angiotensin-converting enzyme 2 activation improves endothelial function.

Authors:  Rodrigo A Fraga-Silva; Fabiana P Costa-Fraga; Tatiane M Murça; Patrícia L Moraes; Augusto Martins Lima; Roberto Q Lautner; Carlos H Castro; Célia Maria A Soares; Clayton L Borges; Ana Paula Nadu; Marilene L Oliveira; Vinayak Shenoy; Michael J Katovich; Robson A S Santos; Mohan K Raizada; Anderson J Ferreira
Journal:  Hypertension       Date:  2013-04-22       Impact factor: 10.190

9.  Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways.

Authors:  Ahmed Z El-Hashim; Waleed M Renno; Raj Raghupathy; Heba T Abduo; Saghir Akhtar; Ibrahim F Benter
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

10.  Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!

Authors:  Vajir Malek; Sachin V Suryavanshi; Nisha Sharma; Yogesh A Kulkarni; Shrikant R Mulay; Anil Bhanudas Gaikwad
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.